Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.
We investigated the effect of a therapeutic dose of raloxifene on the plasma levels of myeloperoxidase and F2alpha-isoprostanes, two markers of oxidative stress recently described as reliable indicators of coronary heart disease. Contrary to changes described in the literature for estrogens (E), raloxifene did not modify the levels of either myeloproxidase or F2alpha-isoprostanes after 3 or 6 months of treatment.
Oviedo
Pilar J
PJ
Department of Pediatrics, Obstetrics and Gynaecology, University of Valencia, Valencia, Spain.
Hermenegildo
Carlos
C
Tarín
Juan J
JJ
Cano
Antonio
A
D000975:Antioxidants / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000517:prevention & control*; D028441:F2-Isoprostanes / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D009195:Peroxidase / Q000097:blood*; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage*
D000975:Antioxidants; D015415:Biomarkers; D028441:F2-Isoprostanes; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D009195:Peroxidase